Results 1 to 10 of about 62,619,193 (270)

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. [PDF]

Musculoskeletal Care, 2022
Background: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterised by musculoskeletal and extra-articular manifestations, most notably psoriasis.
Fragoulis GE, Siebert S.
europepmc   +8 more sources

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. [PDF]

Dermatol Pract Concept
Introduction: IL-17 and IL-23 inhibitors have transformed the management of moderate-to-severe psoriasis and other inflammatory diseases through targeted immune modulation.
Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB.   +4 more
europepmc   +2 more sources

Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis. [PDF]

Dig Dis Sci, 2023
Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, Sands BE, Panaccione R, Narula N, Feagan BG, Singh S, Jairath V, Ma C.   +12 more
europepmc   +1 more source

Hair Loss Associated With IL-17 and IL-23 Inhibitors: A Systematic Review. [PDF]

Int J Dermatol
Gupta S, Liu E, Dhawan J, Peri K, McMullen E, Julanon N, Donovan J.   +6 more
europepmc   +1 more source

Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. [PDF]

Immunol Res, 2023
Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, Zhu H.   +6 more
europepmc   +1 more source

IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? [PDF]

J Inflamm Res
Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L.   +5 more
europepmc   +1 more source

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review. [PDF]

Biomedicines, 2023
Tsiogka A, Gregoriou S, Stratigos A, Soulaidopoulos S, Rompoti N, Panagakis P, Papoutsaki M, Kostakis P, Kontochristopoulos G, Tsioufis K, Campanati A, Offidani A, Vlachopoulos C, Rigopoulos D.   +13 more
europepmc   +1 more source

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. [PDF]

Int J Dermatol
Falco GM, Ippoliti E, Gori N, Caldarola G, De Simone C, Di Giorgi N, Longo PG, Galluzzo M, Bianchi L, Marcelli L, Talamonti M, Cannizzaro MV, Di Nardo L, Peris K.   +13 more
europepmc   +1 more source

Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports

JAAD Case Reports, 2023
Khalid Nabil Nagshabandi, MBBS, Abdulaziz Alsalhi, MBBS, Duaa Alahmadi, MBBS, Sara Almesfer, Abdulmajeed M. Alajlan, MD   +4 more
doaj   +1 more source

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, Burzi L, Castelli F, Chiarpenello M, Graziola F, Leporati C, Ortoncelli M, Pella P, Pertusi G, Pisterna A, Quaglino P, Ribero S, Rossotto G, Tiberio R, Dapavo P, Savoia P.   +20 more
europepmc   +1 more source